Mark J. Biagi
Clinical Assistant Professor, College of Pharmacy - Pharmacy Practice
Clinical Instructor, College of Pharmacy - Pharmacy Practice
Email:
Related Sites:
About Heading link
Teaching and Supervision Heading link
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
Undergrad Resrch Pharm Pract (PMPR 380), 1/9/2023 – 4/28/2023
PDAT 6: Infectious Diseases (PHAR 506), 1/9/2023 – 4/28/2023
Undergrad Resrch Pharm Pract (PMPR 380), 1/11/2021 – 4/30/2021
PHAR 520: Clinical Pharmaceutics, Pharmacokinetics, and Pharmacogenomics (PHAR 520), 8/17/2020 – Present
PHAR 435: Pharmacokinetics (PHAR 435), 8/26/2019 – 12/6/2019
Spec Project in Pharm Pract (PMPR 390), 8/26/2019 – 12/6/2019
Spec Project in Pharm Pract (PMPR 390), 8/26/2019 – 12/6/2019
Antimicrobial Use in Pregnancy, 2018 – Present
Selected Grants
Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU Patients, Merck Sharp & Dohme Corp., 1/6/2022 - 1/6/2025, No Obligated Amount Set; Anticipated Amount: $137232.72
ACTIV-4c: COVID-19 Post-Hospital Thrombosis Prevention Study, National Institutes of Health., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
Real World Multicenter Observational Study of Imipenem-Cilastatin-Relebactam for Gram-Negative Infections, Merck & Co., Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
Multicenter Observational Study of Dalbavancin for Invasive Bloodstream Infections, Allergan Inc.., 4/1/2021 - Present, No Obligated Amount Set; No Anticipated Amount Set
ACTIV-4 ACUTE: COVID-19 Acute Inpatient Antithrombotic Study, National Institutes of Health., 10/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to those on Vancomycin and Ceftolozane-Tazobactam, Merck & Co.., 8/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Real-world experience with eravacycline at academic hospital systems, Tetraphase Pharmaceuticals., 2/1/2020 - Present, No Obligated Amount Set; No Anticipated Amount Set
Aztreonam + ceftazidime/avibactam against Stenotrophomonas maltophilia, Cystic Fibrosis Foundation., 6/1/2019 - 11/30/2020, Obligated Amount: $54000; Anticipated Amount: $54000
Evaluation of omadacycline activity against minocycline-susceptible and –resistant Acinetobacter baumannii, Paratek Pharmaceuticals., 5/2019 - 5/2019, No Obligated Amount Set; No Anticipated Amount Set
Selected Publications
Rebold, Nicholas, Alosaimy, Sara, Pearson, Jeffrey C, Dionne, Brandon, Taqi, Ahmad, Lagnf, Abdalhamid, Lucas, Kristen, Biagi, Mark, Lombardo, Nicholas, Eudy, Joshua, Anderson, Daniel T, Mahoney, Monica V, Kufel, Wesley D, D’Antonio, Joseph A, Jones, Bruce M, Frens, Jeremy J, Baumeister, Tyler, Geriak, Matthew, Sakoulas, George, Farmakiotis, Dimitrios, Delaportas, Dino, Larew, Jeremy, Veve, Michael P, Rybak, Michael J. (2024). Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study. Infectious Diseases and Therapy, 13, (3), 565-579. doi:10.1007/s40121-024-00933-2.
Coyne, Ashlan J Kunz, Alosaimy, Sara, Lucas, Kristen, Lagnf, Abdalhamid M, Morrisette, Taylor, Molina, Kyle C, DeKerlegand, Alaina, Schrack, Melanie Rae, Kang-Birken, S Lena, Hobbs, Athena LV, Agee, Jazmin, Perkins, Nicholson B, Biagi, Mark, Pierce, Michael, Truong, James, Andrade, Justin, Bouchard, Jeannette, Gore, Tristan, King, Madeline A, Pullinger, Benjamin M, Claeys, Kimberly C, Herbin, Shelbye, Cosimi, Reese, Tart, Serina, Veve, Michael P, Jones, Bruce M, Rojas, Leonor M, Feehan, Amy K, Scipione, Marco R, Zhao, Jing J, Witucki, Paige, Rybak, Michael J. (2024). Eravacycline, the first four years: health outcomes and tolerability data for 19 hospitals in 5 U.S. regions from 2018 to 2022. Microbiology Spectrum, 12, (1), e02351-e02323. doi:10.1128/spectrum.02351-23.
Alosaimy, Sara, Lagnf, Abdalhamid M, Hobbs, Athena LV, Mubarez, Musa, Kufel, Wesley D, Morrisette, Taylor, Polisetty, Radhika S, Li, David, Veve, Michael P, Simon, Sam P, Truong, James, Finch, Natalie, Venugopalan, Veena, Rico, Matthew, Amaya, Lee, Yost, Christine, Cubillos, Ashley, Chandler, Elisabeth, Patch, Megan, Smith, Ian Murphy Kelsey, Biagi, Mark, Wrin, Justin, Moore, W Justin, Molina, Kyle C, Rebold, Nicholas, Holger, Dana, Kunz Coyne, Ashlan J, Jorgensen, Sarah CJ, Witucki, Paige, Tran, Nikki N, Davis, Susan L, Sakoulas, George, Rybak, Michael J. (2023). Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.. Clinical Infectious Diseases, 76, (3), e1444-e1455. doi:10.1093/cid/ciac670.
Alosaimy, Sara, Morrisette, Taylor, Lagnf, Abdalhamid M, Rojas, Leonor M, King, Madeline A, Pullinger, Benjamin M, Hobbs, Athena LV, Perkins, Nicholson B, Veve, Michael P, Bouchard, Jeannette, Gore, Tristan, Jones, Bruce, Truong, James, Andrade, Justin, Huang, Glen, Cosimi, Reese, Kang-Birken, S Lena, Molina, Kyle C, Biagi, Mark, Pierce, Michael, Scipione, Marco R, Zhao, Jing J, Davis, Susan L, Rybak, Michael J. (2022). Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiology Spectrum, 10, (5), e00479-e00422. doi:10.1128/spectrum.00479-22.
Vialichka, Alesia, Biagi, Mark, Meyer, Kevin, Wu, Tiffany, Shajee, Aisha, Tan, Xing, Wenzler, Eric. (2022). Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values. Microbiology Spectrum, 10, (4), e02705-e02721. doi:10.1128/spectrum.02705-21.
Abbey, Taylor, Vialichka, Alesia, Jurkovic, Michele, Biagi, Mark, Wenzler, Eric. (2022). Activity of Omadacycline Alone and in Combination against Carbapenem-Nonsusceptible Acinetobacter baumannii with Varying Minocycline Susceptibility. Microbiology Spectrum, 10, (3), e00542-e00522. doi:10.1128/spectrum.00542-22.
Biagi, Mark, Lee, Michelle, Wu, Tiffany, Shajee, Aisha, Patel, Shitalben, Deshpande, Lalitagauri M, Mendes, Rodrigo E, Wenzler, Eric. (2022). Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales. Diagnostic Microbiology and Infectious Disease, 103, (2), 115674. doi:10.1016/j.diagmicrobio.2022.115674.
Rebold, Nicholas, Morrisette, Taylor, Lagnf, Abdalhamid M, Alosaimy, Sara, Holger, Dana, Barber, Katie, Justo, Julie Ann, Antosz, Kayla, Carlson, Travis J, Frens, Jeremy J, Biagi, Mark, Kufel, Wesley D, Moore, William J, Mercuro, Nicholas, Raux, Brian R, Rybak, Michael J. (2021). Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infectious Diseases, 8, (12), ofab554. doi:10.1093/ofid/ofab554.
Lee, Michelle, Abbey, Taylor, Biagi, Mark, Wenzler, Eric. (2021). Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.. Diagnostic Microbiology and Infectious Disease, 99, (1). doi:10.1016/j.diagmicrobio.2020.115227.
Professional Leadership
Clostridioides difficile committee, SwedishAmerican Hospital, 2/1/2020 - Present
Education
Degrees:
Doctor of Pharmacy, University of Illinois at Chicago, United States, 2016
Bachelor of Science, University of Illinois at Chicago, United States, 2012
Postgraduate Training:
PGY-1 Pharmacy Practice Resident, Franciscan Health, United States, 2017